22 Jul

#NewTrialAnnouncement

PharmaSols is delighted to be working with UNITY Biotechnology, Inc. (UNITY) on their latest ophthalmologic study UBX1325-02, across multiple sites in Australia and New Zealand.

The study is a Phase 2a, Prospective, Multicentre, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Oedema (DME).

UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, nAMD, and DR.

UNITY and PharmaSols look forward to forging a strong on-going relationship. As UNITY expands its global footprint with clinical studies, they are very excited to include AU and NZ in this important effort.

Find out more https://lnkd.in/g_MXh9U

Other News

How Biotechs can utilise Australia and New Zealand to extend seasonal clinical trials and rescue studies

Randomised, controlled trials are considered the gold standard in assessing the safety and effectiveness of potential new medicines and therapies.

Read more
The Effect of the Pandemic on locations for conducting clinical trials for Biotechs

Through the spring of 2020, it became evident that the Covid-19 pandemic would have a dual impact on the clinical research sector. While it has provided the opportunity to conduct research for vaccines, treatments, and diagnostic tests for COVID-19; it has also acted as a major disruptive force, halting trials in their tracks, and exacerbating existing fragilities within the sector.

Read more
Global Clinical Trials take advantage of significant Australian R&D tax incentives

Australia and New Zealand are well-established regions for international clinical trials.  Global sponsors understand the region’s ability to deliver quality research outcomes; rapid start-up, recruitment and participant retention, streamlined ethics and regulatory pathways, internationally accepted quality data from world-leading research facilities and Investigators. 

Read more